<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0380">
 <label>76</label>
 <element-citation publication-type="journal" id="rf0380">
  <person-group person-group-type="author">
   <name>
    <surname>Kiessling</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Lledo-Garcia</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Watanabe</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Langdon</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Tran</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Bari</surname>
    <given-names>M.</given-names>
   </name>
  </person-group>
  <article-title>The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study</article-title>
  <source>Sci Transl Med</source>
  <volume>9</volume>
  <year>2017</year>
  <pub-id pub-id-type="doi">10.1126/scitranslmed.aan1208</pub-id>
 </element-citation>
</ref>
